Model-based versus patient-specific dosimetry: Blurring the lines

Journal of Nuclear Medicine

Volumn 43, Issue 12, 2002, Pages 1665-1666

  Zanzonico, Pat B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

BONE MARROW SUPPRESSION; DOSIMETRY; GASTROINTESTINAL TRACT; HUMAN; MEDICAL LITERATURE; METHODOLOGY; MODEL; NOTE; ORGANIZATION; PRIORITY JOURNAL; RADIATION ENERGY; RADIODIAGNOSIS;

HUMANS; INTESTINE, SMALL; MODELS, BIOLOGICAL; RADIATION DOSAGE;

EID: 0036898677     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (27)

1. Jönsson L, Liu X, Jönsson B-A, et al. A dosimetry model for the small intestine incorporating intestinal wall activity and cross-doses. J Nucl Med. 2002;43:1657-1664.
2. Watson EE, Foreward. J Nucl Med. 1999:40(suppl):1S-2S.
3. Loevinger R. The MIRD perspective. In: Adelstein S, Kassis A, Burt R, eds. Dosimetry of Administered Radionuclides. Washington, DC: American College of Nuclear Physicians/Department of Energy; 1989:29-43.
4. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Revised. New York, NY: Society of Nuclear Medicine; 1991.
5. Howell RW, Wessels BW, Loevinger R, in collaboration with the MIRD Committee. The MIRD perspective 1999. J Nucl Med. 1999;40(suppl):3S-10S.
6. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. ICRP Publication 53. New York. NY: Pergamon Press: 1988.
7. Poston JW Jr, Kodimer KA, Bolch WE, Poston JW Sr. A revised model for the calculation of absorbed energy in the gastrointestinal tract. Health Phys. 1996:71:307-314.
8. Stubbs JB, Evans JF, Stabin MG. Radiation absorbed doses to the walls of hollow organs. J Nucl Med. 1998;39:1989-1995.
9. Jönsson B-A, Strand SE, Larsson BS. A quantitative autoradiographic study of the heterogeneous activity distribution of different indium-111-labeled radiopharmaceuticals in rat tissues. J Nucl Med. 1992;33:1825-1833.
10. Thomas SR. Options for radionuclide therapy: From fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm. 2002;17:71-82.
11. Zanzonico PB. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308.
12. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49-53.
13. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med. 1996;37:1970-1975.
14. Sgouros G, Barest G, Thekkumthala J, et al. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31:1884-1891.
15. Zanzonico P, Edwards C, Sgouros G, et al. Practical dosimetry: quantitative imaging in radionuclide therapy. In: Adelstein S, Kassis A, Burt R. eds. Dosimetry of Administered Radionuclides. Washington, DC: American College of Nuclear Physicians/Department of Energy; 1989:275-294.
16. Erdi AK, Erdi YE, Yorke ED, Wessels BW. Treatment planning for radio-immunotherapy. Phys Med Biol. 1996;41:2009-2026.
17. Zanzonico PB, Bigler RE, Sgouros G, Strauss A. Quantitative SPECT in radiation dosimetry. Semin Nucl Med. 1989;19:47-61.
18. Zanzonico P, Brill A, Becker D. Radiation dosimetry. In: Wagner H, Szabo Z, Buchanan J. eds. Principles of Nuclear Medicine, 2nd ed. Philadelphia. PA: W.B. Saunders: 1995:106-134.
19. Benua R, Cicale N, Sonenberg M. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. 1962;87:171-182.
20. Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 1999;40:131-136.
21. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
22. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
23. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase 1 experience. J Nucl Med. 1998;39(suppl):21S-27S.
24. Zasadny KR, Gates VL, Fisher SJ, Kaminski MS, Wahl RL. Correlation of dosimetric parameters with hematological toxicity after radioimmunotherapy of non-Hodgkin's lymphoma with I-131 anti-B1: Utility of a new parameter - "Total body dose-lean" [abstract]. J Nucl Med. 1995;36(suppl):214P.
25. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
26. Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet. 2001; 358:1102-1103.
27. Otte A, Weiner SM, Cybulla M. Is radiation nephropathy caused by yttrium-90? Lancet. 2002;359:979.